Status:
COMPLETED
Effect of SLC01B1 (rs4149956) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population
Lead Sponsor:
Riphah International University
Conditions:
Hyperlipidemias
Eligibility:
All Genders
40-70 years
Brief Summary
The goal of this prospective cohort study was to identify the effect of SLC01B1 gene polymorphism in the Pakistani population. The main questions it aims to answer are: To identify polymorphism in SLO...
Detailed Description
The goal of this prospective cohort study was to identify the effect of SLC01B1 gene polymorphism in the Pakistani population, due to the high prevalence of this variant in the Pakistani Population Th...
Eligibility Criteria
Inclusion
- Pakistani individuals aged between 40 to 70 years
- Patients with deranged lipid profile
- Newly diagnosed patients of dyslipidemia taking atorvastatin (Lipiget) 10mg/day
- Normal hepatic and renal function
Exclusion
- Patient taking other lipid-lowering medications
- Moderate and severe systemic diseases
- Pregnancy
- Patients taking medications and diet that can interact with atorvastatin
- Hypothyroidism
- Recent history of surgical procedure or trauma
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07148037
Start Date
September 1 2024
End Date
July 31 2025
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Riphah International University
Rawalpindi, Punjab Province, Pakistan